Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR2 | O95136 | 11/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.46 |
| ▸ | CCR1 | P32246 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5912322 | 0.92 | S1PR2 (0.61) | S1PR2NPSR1POLBMAPT | |
| SCHEMBL5912698 | 0.91 | NPSR1 (0.58) | S1PR2NPSR1MAPTKMT2AMEN1 | |
| SCHEMBL5912592 | 0.87 | NPSR1 (0.58) | S1PR2NPSR1POLBMAPTPKM | |
| SCHEMBL5912441 | 0.85 | S1PR2 (0.68) | S1PR2NPSR1POLBMAPTKMT2A | |
| SCHEMBL5912433 | 0.83 | S1PR2 (0.67) | S1PR2MAPTOPRL1KDM4E | |
| SCHEMBL5912081 | 0.82 | S1PR2 (0.64) | S1PR2NPSR1POLBMAPTKMT2A | |
| SCHEMBL5912182 | 0.82 | S1PR2 (0.58) | S1PR2NPSR1POLBMAPT | |
| SCHEMBL5912631 | 0.82 | S1PR2 (0.68) | S1PR2NPSR1POLBMAPTKMT2A | |
| SCHEMBL5912423 | 0.81 | SMN1; SMN2 (0.54) | S1PR2NPSR1POLBMAPTPKM | |
| SCHEMBL5911933 | 0.81 | NPSR1 (0.51) | S1PR2NPSR1POLBMAPTPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2508204-B1 | Remedies for diseases caused by vascular contraction or dilation | ONO PHARMACEUTICAL CO (JP) | 2014-09-24 | — | — | EP | disclosed |
| US-8765783-B2 | Pharmaceutical composition for treatment of disease due to vascular constriction or vasodilation | ONO PHARMACEUTICALS CO., LTD. (JP) | 2014-07-01 | — | — | US | disclosed |
| EP-1522314-B1 | REMEDIES FOR DISEASES CAUSED BY VASCULAR CONTRACTION OR DILATION | ONO PHARMACEUTICAL CO (JP) | 2014-03-05 | — | — | EP | disclosed |
| EP-2508204-A2 | Remedies for diseases caused by vascular contraction or dilation | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-10-10 | — | — | EP | disclosed |
| US-20060148844-A1 | Pharmaceutical composition for treatment of disease due to vascular constriction or vasodilation | ONO PHARMACEUTICAL CO., LTD | 2006-07-06 | — | — | US | disclosed |
| EP-1522314-A1 | REMEDIES FOR DISEASES CAUSED BY VASCULAR CONTRACTION OR DILATION | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-04-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148844-A1 | Pharmaceutical composition for treatment of disease due to vascular constriction or vasodilation | EDNRA, EDNRB, CACNG5 | S1PR2 480/4885NPSR1 676/4885POLB 4836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.